Zheng Quan Ri Bao Wang·2025-12-19 02:10Core Viewpoint - Guangzhou Pharmaceutical Holdings Limited's subsidiary, Guangzhou Medicine, successfully acquired 100% equity of Zhejiang Pharmaceutical Industry Co., Ltd. from Zhejiang Haizheng Pharmaceutical Co., Ltd. for 500.5 million yuan, marking a significant strategic move in the East China market and highlighting the accelerated integration in the pharmaceutical distribution industry [1][2]. Group 1: Transaction Details - The acquisition began with a public transfer, where Guangzhou Medicine successfully bid 500.5 million yuan on December 10 and paid a deposit of 86 million yuan [1]. - The formal signing of the equity transaction contract and supplementary agreement occurred on December 17, with the total transfer price set at 500.5 million yuan [1]. Group 2: Strategic Importance - Zhejiang Pharmaceutical is a leading pharmaceutical distribution company in Zhejiang, with a distribution network covering over 99% of public hospitals in the province, making it a key asset for the acquisition [1][2]. - The acquisition is not merely an asset transfer but a strategic alignment that aims to create synergistic effects, enhancing the long-term development of Guangzhou Pharmaceutical [2]. Group 3: Competitive Advantages - Zhejiang Pharmaceutical possesses unique qualifications for operating and distributing specific drugs, which are scarce in the regional market, providing a competitive edge [2]. - The company has a well-established distribution network across Zhejiang and has built strong relationships with government and enterprise clients, securing a stable market share in the Yangtze River Delta pharmaceutical distribution market [2]. Group 4: Future Business Ecosystem - Post-acquisition, Guangzhou Medicine plans to leverage Zhejiang Pharmaceutical's established medical terminal network and commercial channels to create a comprehensive business ecosystem that includes hospital sales, retail distribution, and smart supply chain solutions [3]. - This strategy aims to accelerate the implementation of innovative businesses such as pharmaceutical e-commerce in the Yangtze River Delta region, enhancing patient services through cold chain delivery and clinical pharmacy services [3].